▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #4016 by analyst upside · 2026-11-13
MEDP
Medpace Holdings, Inc.
Healthcare · Market Cap $18B · P/E 36.5x
ANALYST PRICE TARGET
-0.8%
implied upside to consensus target
Current Price $656.84
Consensus Target $651.31
Bull Target $730.0
Bear Target $370.0
Analysts Covering 13
ANALYST CONSENSUS - HOLD
Strong Buy
1
Buy
1
Hold
10
Sell
1
52-Week Low $373.0
52-Week High $693.97
YTD Return +15.0%
FUNDAMENTALS
Market Cap $18B
P/E Ratio (TTM) 36.5x
Forward P/E 33.1x
EPS (TTM) $18.01
PEG Ratio 3.42
Dividend Yield N/A
Revenue (TTM) $2.8B
Profit Margin 18.2%
52-WEEK RANGE
52-Week Low $373.0
52-Week High $693.97
Current Price $656.84
Bear Target $370.0
Bull Target $730.0
● Now $656.84 ● Target $651.31
TRADING DATA
Avg Volume 258K
YTD Return +15.0%
Analyst Count 13
Consensus Hold
Upside to Target -0.8%
Last Updated 2026-11-13

ANALYST SUMMARY

Medpace Holdings, Inc. (MEDP) is currently trading at $656.84 with a Wall Street consensus price target of $651.31, which is 0.8% below the current price over the next 12 months. 13 analysts currently cover MEDP, with a consensus rating of Hold - 15% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $730.0, while the most cautious has a target of $370.0.

MEDP operates in the Healthcare sector with a market capitalisation of $18B. The stock is up 15.0% year-to-date and is currently trading near the upper end of its 52-week range of $373.0 – $693.97.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

EXEL -11.8%
Exelixis, Inc.
$17B · P/E 20.9x · Hold
WST +14.5%
West Pharmaceutical Services, Inc.
$29B · P/E 46.2x · Buy
STE +10.9%
STERIS plc
$25B · P/E 30.1x · Buy
ZBH +11.2%
Zimmer Biomet Holdings, Inc.
$20B · P/E 26.4x · Hold
MTD +0.4%
Mettler-Toledo International Inc.
$34B · P/E 37.6x · Hold

RECENT ANALYST CALLS

Upgrade/downgrade history for MEDP, with each firm's 90-day track record across all stocks we track. See full firm rankings →

BMO Capital - Reiterated
Market Perform → Market Perform 2026-10-26 Building track record
UBS - Reiterated
Neutral → Neutral 2026-10-23 33% win rate (6 calls)
Truist Securities - Reiterated
Hold → Hold 2026-10-23 Building track record
Barclays - Reiterated
Equal-Weight → Equal-Weight 2026-10-23 Building track record
TD Cowen - Reiterated
Hold → Hold 2026-10-23 Building track record
Mizuho - Reiterated
Outperform → Outperform 2026-10-07 Building track record
Barclays - Reiterated
Equal-Weight → Equal-Weight 2026-10-07 Building track record
UBS ↑ Upgrade
Sell → Neutral 2026-09-30 33% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
41
out of 100
Coverage depth
20/30
Consensus clarity
19/30
Vote unanimity
0/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →